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Available online 14 June 2016Objective: The objective of this study was to examine cognitive and quality-of-life measures/quality of life out-
comes with adjunctive lacosamide therapy in patients with treatment-resistant partial epilepsy.
Methods: This was a prospective, open-label, nonblinded, adjunctive therapy test–retest (within subjects) study
of patients with treatment-resistant partial epilepsy in which outcome (cognitive functioning and mood/quality
of life) was measured in the same subject before and after adjunctive lacosamide administration for 24 weeks.
The cognitive assessment included the following: Controlled Oral Word Association Test, Buschke Selective
Reminding Test, Brief Visuospatial Memory Test—Revised, Stroop Color Word Test, Symbol Digit Modalities
Test, Digit Span, Digit Cancellation, and Trails A and B. The quality-of-life measures/quality-of-life assessment in-
cluded the following: Beck Depression Inventory—II, Proﬁle of Mood States, and Quality of Life Inventory—89.
Lacosamide was started at 100 mg (50 mg twice daily) and could be titrated as needed up to 400 mg/day
(200 mg twice daily). Baseline concomitant AEDs were kept constant. Composite scores were calculated for a
pre–post difference score for the cognitive and mood/quality-of-life measures separately and used in regression
analyses to correct for the effects of age, education, seizure frequency, seizure severity, dose of lacosamide, and
number of AEDs at baseline.
Results: Thirty-four patientswere enrolled (13males, 21 females). Mean agewas 38.8± 2.43 years.Mean seizure
frequency decreased signiﬁcantly from 2.0± 2.55 seizures perweek at baseline to 1.02± 1.72 seizures perweek
at posttreatment (t = 4.59, p b .0001) with a 50% responder rate seen in 18 patients (52.9%). No signiﬁcant dif-
ferenceswere foundon the composite scores of the cognitiveor themood/quality-of-lifemeasures after 6months
of lacosamide.
Signiﬁcance: Lacosamide appeared to have low risks of signiﬁcant changes in cognition ormood/quality of life. In
addition, the present study supports prior studies that have proven lacosamide as an effective adjunctive therapy
for the treatment of resistant partial epilepsy.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Refractory1. Introduction
Lacosamide is a third-generation antiepileptic drug available inmul-
tiple formulationswhichwas approved as adjunct treatment for partial-
onset epilepsy in adults by the US Food and Drug Administration (FDA)
in 2008 and as monotherapy in 2014. Three randomized, controlled tri-
als (RCTs) of lacosamide as adjunct treatment for medically intractable
epilepsy [1–3] and three long-term follow-up studies [4–6] revealed ay Group, 20 Prospect Ave, Suite
fax: +1 914 428 9282.
fertig.evan@gmail.com
r), krp2003@med.cornell.edu
pilepsygroup.com (S.S. Iyengar),
. This is an open access article undersigniﬁcant anticonvulsant effect. Lacosamide has also demonstrated
a good safety proﬁle with a small degree of adverse events. The most
common adverse events reported were diplopia, dizziness, nausea,
and headaches [1–6].
Limited data exist regarding the effect of lacosamide on mood and
cognition. In the pooled analysis of adverse effects (AEs) from the
3 RCTs [1–3], self-reported rates of “memory impairment” were seen
in 2% of the composite treatment arm vs. 1% in the placebo arm, and
depression was noted in 2% in the composite treatment arm vs. 1% in
the placebo arm. Lacosamide, like all other AEDs, has a warning for
suicidality though there are no speciﬁc data to suggest an increased
risk. Other data regarding mood/cognition have been limited to
small prospective uncontrolled or retrospective studies. IJff et al. [7]
studied patientswith refractory partial-onset epilepsy prospectively be-
fore and after lacosamidewas added as adjunctive therapy. The authorsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Schematic diagram showing the ﬂow of the study (* refers to an optional safety visit
after the studywas completed. Subjects could choose to stop taking the drug at this point;
the subjects that elected to stay on lacosamide received it as a prescription medication).
NP = neuropsychological testing.
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jectively, they did not doworsewith lacosamide on a computerized task
[7]. Helmstaedter and Witt retrospectively studied the impact of ad-
junctive lacosamide and compared it with that of topiramate and
lamotrigine in a naturalistic outpatient setting and concluded that cog-
nitive effectswere equivalent to lamotrigine and better than topiramate
[8]. As for mood, the effects of lacosamide on depression and anxiety
were retrospectively studied in patients with partial-onset epilepsy by
Moseley et al. [9]. The authors concluded that lacosamide did not wors-
en depression or anxiety. Giorgi et al. [10] conducted a small study
assessing depression and anxiety on 10 patients and found no changes
after the use of lacosamide.
Understanding the cognitive and behavioral side effect proﬁle of
AEDs is important to clinical practice since changes in these areas
could affect quality of life and adherence with the medication. This
study is the ﬁrst prospective comprehensive study of cognitive and
mood/quality-of-life side effects of lacosamide on patients with refrac-
tory partial epilepsy using a neuropsychological battery of tests for as-
sessment of attention, concentration, psychomotor speed, verbal and
nonverbal learning and verbal ﬂuency, as well as mood/quality-of-life
measures and evaluation of adverse/side effects. In contrast to the
other two prospective studies, we used a testing battery that was inclu-
sive and sensitive to a range of cognitive functions.
Our study had two objectives: to investigate whether lacosamide
affects cognition andmood/quality of life and to determine if any signif-
icant changes in cognition or mood/quality of life were dependent
on covariates including age, sex, education, number of AEDs, seizure
frequency and seizure severity at baseline, and ﬁnal drug dose at the
end of the trial.
2. Methods
2.1. Patient population and study design
This was a prospective, open-label, nonblinded, adjunctive therapy
test–retest (within subjects) study of patients with uncontrolled
partial epilepsy in which outcome (cognitive functioning and mood/
quality of life) was measured in the same subject before and after
adjunctive lacosamide administration. This design was chosen since
it best emulates what occurs in clinical practice. All procedures were
done with prior approval from the Copernicus Group IRB (CGIRB;
Durham, NC) #: MLA1-10-124.
The inclusion criteriawere as follows: (1) ages 18–70 years; (2) able
andwilling to providewritten informed consent in accordancewith the
International Conference on Harmonisation (ICH) and Good Clinical
Practice (GCP) guidelines; (3) a native English speaker or balanced
bilingual; (4) diagnosis of refractory partial-onset epilepsy; and (5) his-
torical mean seizure frequency of at least 2 seizures per month for the
6 months prior to the ﬁrst visit.
The exclusion criteria were as follows: (1) subjects with a history of
drug or alcohol abuse; (2) pregnant females or those using an unreliable
method of contraception; (3) diagnosis of a major psychiatric disorder
(bipolar disorder, schizophrenia, psychotic disorder, major depression)
requiring hospitalization in the past 2 years or the presence of other
psychological or behavioral conditions that the investigator judged
should grounds for exclusion from the study; (4) currently using an
antidepressant, anxiolytic, or antipsychotic agent; (5) active suicidal
plan or suicidal thoughts in the past 6 months; (6) presence of a pro-
gressive, demyelinating, or degenerative neurological condition; (7) di-
agnosis of psychogenic nonepileptic seizure disorder; (8) a history of
traumatic brain injury or of cardiac arrhythmia; and (9) impaired intel-
ligence quotient (estimated Full Scale IQ b 70).
Withdrawal criteria included the following: (1) subjects who en-
dorsed suicidality, (2) any episode of status epilepticus, (3) need for
use of rescue benzodiazepinemore than once per week, (4) any labora-
tory abnormalities which were deemed by the investigator to beclinically signiﬁcant, (5) any clinically signiﬁcant objective clinical
signs or symptoms that were intolerable or incapacitating to the patient
and/or pose a serious threat towell-being, (6) nonadherencewith study
protocol (b80% compliance with study medication), (7) females who
became pregnant during the study, (8) and voluntary withdrawal by
the patient.
Study subjectswere referred by aNortheast Regional EpilepsyGroup
neurologist in New York and New Jersey between August 2010 and
March 2015.2.2. Study visits
The study was spread over 28 weeks and was divided into three
phases: screening (visit 0), titration/treatment phase (visits 1, 2, 3), and
termination phase (visit 4) (Fig. 1). Screening duration was 4 weeks,
visit 1 was at 4 weeks after screening, visit 2 at 6 weeks, visit 3 at
18 weeks, and visit 4 (termination phase) at 28 weeks. Telephone
calls were made 2 weeks after screening and at weeks 6, 10, 14, 22, and
26 to obtain seizure frequency and seizure severity data to assess com-
pliance with the daily diary and to monitor adverse events and changes
in concomitant medications.
At the screening visit (visit 0), eligibility assessmentwas performed,
and written informed consent was obtained. Baseline demographic
data included seizure history, type and frequency, AED use history,
medical history, and psychiatric history collected. Measurement of
vital signs, body weight, and height and physical and neurological ex-
aminationwere performed. Laboratory safety studies (urinalysis, hema-
tology, chemistries, and serum or urine pregnancy tests as appropriate)
and urine pregnancy tests were obtained. Subjects were trained in
maintenance of a seizure diary to be kept throughout the study. After
the screening visit, laboratory testing was done only if clinically
indicated.
Over a 4-week baseline period, subjects were assessed on compli-
ance with the daily diary, and screening test results were reviewed
with a telephone call from the study coordinator at week 2. All concom-
itant AEDs were kept stable during the 4-week baseline period.
During visit 1 (week 4), inclusion and exclusion criteria and seizure
diaries were reviewed. If the subject still met the eligibility criteria, the
drug was dispensed as described below (Section 2.3). During all visits
after the screening visit (visits 1, 2, 3, 4), physical and neurological ex-
aminations were performed, and vital signs, seizure frequency, seizure
severity, and adverse events data were collected.
After completion of the study, subjects were given an option to taper
off the drug after visit 4 (i.e., after aminimumof 28weeks into the study).
In this study, 3 out of the 34 subjects elected to taper off medication. Sub-
jects who wished to remain on the drug continued to receive it as a pre-
scription medication. A summary of the protocol can be seen in Table 1.
Table 1
Table showing schedule of assessments for the study.
Screening Phone
call
Visit 1 Visit 2 Phone
call
Phone
call
Visit 3 Phone
call
Phone
call
Visit 4 Visit 5
(Titration) (Treatment) (Treatment) (Termination) (Safety)
Week 0 Week 2 Week 4 Week 6 Week 10 Week 14 Week 18 Week 22 Week 26 Week 28 Week 30
Written informed consent X
Demographic data X
Veriﬁcation of inclusion exclusion criteria X X
Medical history X
Physical and neurological examination X X X X X X
Neuropsychological testing X X
Routine lab test X X X
Pregnancy test X X
Vital signs X X X X X X
Adverse event proﬁle,
A–B Neurotoxicity Proﬁle
X X
Drug dispensing and accountability X X X X
Seizure diary review X X X X X X X X X X
Liverpool Seizure Severity Scale X X
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Lacosamide was provided by UCB (Brussels, Belgium) in the form
of capsules containing 50mg, 100mg, 150mg, and 200mg. Lacosamide
was dispensed at 50mgbid (100mg total daily dose) at visit 1. Drug ad-
herence was calculated at all visits. All concomitant medications for ep-
ilepsy were kept stable throughout the study.
The dose of lacosamide was adjusted throughout the course of the
study by the investigator depending on the seizure frequency and se-
verity and adverse event proﬁle of the subject. The standard study
drug-dosing schedule was as follows: lacosamide was titrated starting
from visit 1 for 2weeks (50mgbid) up to a therapeutic dosage as deter-
mined by the investigator with a maximum of 400 mg/day.
2.4. Analysis of seizures
Subjects were interviewed at baseline to characterize their seizure
types and then assigned a code to enter into the seizure diary. Diaries
were reviewed at each visit by the study coordinator and PI to deter-
mine seizure frequency. The predrug baseline seizure frequency
was calculated over 28 days prior to visit 1. The two-week-long initial
titration period after visit 1 was not taken into account for the ﬁnal
frequency count. The postdrug seizure count was taken as the raw
number of seizures which was over the remaining 22 weeks of drug
treatment.
Severity of seizures was assessed through the use of the Liverpool
Seizure Severity Scale 219 [11]. This scale has 12 questions which pro-
vide a single score for seizure severity. The Liverpool Seizure Severity
Scale was given at baseline and at the end of the study (visit 4) at
28 weeks.
2.5. Adverse event monitoring
An adverse event was deﬁned as any untoward medical occurrence
without necessarily a causal relationship with the treatment (i.e.,
lacosamide). This could include clinically signiﬁcant symptoms and
signs, changes in physical examination ﬁndings, abnormal laboratory
test ﬁndings, hypersensitivity, and worsening of epilepsy. Adverse
events were assessed in three different ways: 1) by documenting all ad-
verse reactions as well as their intensity (mild, moderate, or severe)
throughout the study and whether any action was taken, 2) by using
an adverse event proﬁle, and 3) with the A–B neurotoxicity proﬁles.
The adverse event proﬁle captures nineteen types of adverse events
[12–14] rated on a 4-point Likert scale with 1, never a problem; 2, rarely
a problem; 3, sometimes a problem; and 4, always a problem. The A–B
neurotoxicity proﬁles [15] capture central nervous system side effectsthrough 33 questions that reﬂect how the individual perceives his/her
cognitive/behavioral functioning. Higher scores represent greater cog-
nitive interference.
2.6. Neuropsychological testing
Theneuropsychological test batterywas derivedusing several guiding
principles. Whenever possible, tasks from previous research on AEDs by
American investigators, which are sensitive to AED effects, were adminis-
tered in a standardized manner and were sensitive to the measurement
of speciﬁc cognitive functions were selected. Consequently, even though
the current study was not performing a direct drug to drug comparison,
inferences could be made from the effects of lacosamide to other AEDs
with similar study protocols. Additionally, tests were chosen based on
short length and relatively low difﬁculty levels in order to reduce subject
dropout.
Neuropsychological testing was divided into cognitive and mood/
quality-of-life measures and was done at visits 1 and 4 to analyze
changes from pre­ to posttreatment. The cognitive tests were selected
to assess speciﬁc domains. TheWechsler Test of Adult Reading provided
a premorbid intellectual quotient estimate at the ﬁrst test session.
Memory was assessed with the Buschke Selective Reminding Test [16]
and the Brief Visuospatial Memory Test—Revised [17,18]. TheWechsler
Adult Intelligence Scale—III Digit Span test [19] assessed attention.
Cognitive speed and inhibition were measured with the Stroop Color
Word Test [16], psychomotor speed and alternation of cognitive set
was assessed with the Trail Making Test [16], visuomotor speed was
tested with the Symbol Digit Modalities Test [16], and timed verbal
and semantic ﬂuency were tested with the Controlled Oral Word Asso-
ciation Test and a categorical ﬂuency measure [16]. The second test ad-
ministration used parallel forms for the followingmeasures: Controlled
Oral Word Association Test, Buschke Selective Reminding Test, Brief
Visuospatial Memory Test, Symbol Digit Modalities Test, and Digit Can-
cellation Test. Mood/quality-of-life assessment included the following:
the Beck Depression Inventory — Second Edition to assess depressive
symptoms [20], the Proﬁle of Mood States (POMS) [21] for multiple
mood states, and theQuality of Life in Epilepsy Inventory—89 for quality
of life (QOLIE-89) [22]. Selected scales from the QOLIE-89 that are the
most sensitive to epilepsy and AED effects were examined to reduce
the number of variables (attention, language, memory, and overall).
The question of practice effects when conducting test–retest trials is
an important factor in neuropsychology. Fortunately, “except for single
solution tests and others with a signiﬁcant learning component, large
changes between test and retest are not common” [23].
Whenever possible, our study employed tests that have an alternate
form (Form A administered in Trial 1 and Form B administered in Trial
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Symbol Digit Modalities Test, the Digit Cancellation Test, the Buschke
Selective Reminding Test, and the Brief Visual Memory Test—Revised.
Alternate versions were not found for the Wechsler Adult Intelligence
Scale—III Digit Span, Animal Naming Test, Stroop Color–Word Test,
and Trail Making Test. For potential practice effects on tests that did
not have alternate forms, we referred to the Practitioner's guide to eval-
uating change with neuropsychological assessment instruments [23]
which provides a comprehensive review of hundreds of studies pre-
senting the results of repeated testing of both control and speciﬁed pa-
tient groups. The following are excerpts from this text for each of the
tests we used that lacked alternate forms:
Digit Span: Although data were not presented for the version
from the newerWAIS-III we used, data with nearly identical stimuli
and presentation were available for theWMS-R. A review of studies
with this version shows practice effects to be negligible, generally
falling below one point [23–25].
Animal Naming: Data for healthy controls show negligible improve-
ments of less than one point [23,26,27].
Stroop Color Word Test: Data for healthy controls from Golden's
version show minor improvements of less than 4 points for word,
one-half point for color, and a slight decline for color–word [23,26],
all with large standard deviations.
Trail Making Test: Data for controls on Trails A and B show such sig-
niﬁcant discrepancies between the cited studies as tomake compar-
isons impossible.
2.7. Data analysis
The SPSS 22.0 software was used to assess cognitive functioning and
mood/quality of life in those taking lacosamide which was the primary
endpoint. In order to reduce the number of variables, a mean standard-
ized difference score was calculated separately for the mood/quality of
life and cognitive measures to produce a behavioral composite and a
cognitive composite. A difference score was calculated between the
predrug and postdrug evaluations for each of the variables (Table 2).
The difference score for each measure was then standardized (Z
score), and the mean difference score across measures was calculated.
This method produced one cognitive composite and one mood/quali-
ty-of-life composite representing change over the duration of the drug
trial. These composites were individually subjected to a Kolmogorov–
Smirnov test to determine ﬁt to a normal distribution in order to deter-
mine if the use of a one-sample t-test would be valid. Statistical signiﬁ-
cance for the two-sided one-sample t-test was set at p b 0.05.Table 2
Table showing data for various cognitive variables — the tasks administered and the numbe
lacosamide administration (‘Pre’), after lacosamide (‘Post’) and difference (‘Diff’) are shown, as
Task n Mean Pre SE Pre Mea
Buschke total 33 76.15 3.906 83.
Buschke delayed recall 33 6 0.6 6.
Brief Visuospatial Memory Test—Revised Trial 1 33 3.18 0.464 4.
Brief Visuospatial Memory Test—Revised Total 33 15.09 1.573 17.
Brief Visuospatial Memory Test — Revised delayed recall 33 5.88 0.672 6.
Wechsler Adult Intelligence Scale—III Digit Span 32 14.06 0.964 12.
Stroop Color Word Test — Word naming 34 71.97 2.788 75.
Stroop Color Word Test — Color naming 34 54.15 2.189 54.
Stroop Color Word Test — Inhibition 34 28 1.802 31.
Stroop interference 34 −2.24 1.707 1.
Symbol Digit Modalities Test 34 37.94 2.04 39.
Trail Making Test A 34 47.97 3.809 47.
Trail Making Test B 32 112.97 8.16 125.
Controlled Oral Word Association Test 34 29.21 2.097 28.
Animal Naming Test 33 14.61 0.699 15.
Digit Cancellation Test 32 125.25 8.25 130.
Digit Cancellation Test Errors 32 6 1.353 9.The secondary objective was to determine whether changes in
cognition or mood were dependent upon the predictors of age, sex,
education, number of AEDs at screening, seizure severity and seizure
frequency after the baseline, and ﬁnal drug dose at visit 4. For this anal-
ysis, a full linear model with stepwise regression was run separately for
the mood composite and the cognitive composite as dependent vari-
ables and the six predictor variables as covariates. If the residuals from
the regressions were normally distributed, the p-values of the t-tests
in the backward stepwise selection procedure were deemed accurate.
The optimal model was determined to be signiﬁcant if the intercept
from the regression was signiﬁcant at p b 0.05.
In order to also determine individual differences, signiﬁcance was
established as ±2 SD from the group mean for cognitive and mood
composite scores.
To understand the effects of lacosamide on different domains, paired
sample t-tests were performed on the predrug and postdrug cognitive
and mood variables, with a Bonferroni correction applied within each
to determine statistical signiﬁcance (p b 0.003 for the cognitive mea-
sures and p b 0.004 for the mood measures).
Another analysis was made of seizure frequency, seizure severity,
neurotoxicity, and adverse proﬁle scales before and after treatment
with a one-sample paired t-test. Statistical signiﬁcance for this two-
sided t-test was set at p b 0.05. The effect size (Cohen's d) was calculated
for each of the change scores for the cognitive and mood variables.3. Results
3.1. Demographics
A total of 36 subjects were enrolled and started on lacosamide. One
discontinued because of relocation, and one patientwas disqualiﬁed be-
cause data fromone trialwere corrupted and lost. Thus, a total of 34 sub-
jects (13 males and 21 females) completed the study. The average age
was 38.8 ± 2.43 years, and average education was 13.2 ± 0.34 years.
Sixteen patients were Caucasians, 10 were African-American, and 8
were Hispanic. Mean dose of lacosamide at visit 4 was 235 mg/day.
The average number of concomitant AEDs that subjects were taking at
the time of screening was 2.0 ± 0.14. Nine subjects were on 1 AED, 16
subjects were taking 2 AEDs, 7 subjects were on 3 AEDs, and 2 subjects
were on 4 AEDs. Twenty patients had temporal lobe epilepsy (10 left, 5
right, and 5 bilateral), 6 had frontal lobe epilepsy (1 left, 2 right, 2 bilat-
eral, 1 undetermined), and 8 had partial epilepsy without further local-
ization (3 right, 1 left, 3 undetermined, 1 bilateral). Details for each
patient can be seen in Table 3.r of subjects for the particular task (n) are shown. Mean and standard error (SE) before
well as ‘t’ and ‘p’ values.
n Post SE Post Mean Diff SE Diff t p Effect Size — Cohen's d
48 4.356 7.3333 2.72324 2.693 0.011 0.468766497
03 0.566 0.0303 0.41852 0.072 0.943 0.01260287
12 0.507 0.9394 0.43723 2.148 0.039 0.374010361
48 1.552 2.3939 1.0435 2.294 0.028 0.39935266
7 0.572 0.8182 0.4615 1.773 0.086 0.308624785
97 0.832 −1.0625 0.49582 −2.143 0.04 0.378817391
88 3.141 3.9118 2.20935 1.771 0.086 0.303649565
03 2.155 −0.1176 1.19175 −0.099 0.922 0.016923208
32 1.74 3.3235 1.13581 2.926 0.006 0.50182297
76 2.186 4 1.80907 2.211 0.034 0.379197234
09 1.879 1.1471 1.12509 1.02 0.315 0.174853591
85 4.755 −0.1176 2.77748 −0.042 0.966 0.007261343
06 15.221 12.0938 12.1401 0.996 0.327 0.176102503
09 2.254 −1.1176 1.33295 −0.838 0.408 0.143791454
48 0.93 0.8788 0.7041 1.248 0.221 0.217269485
19 5.943 4.9375 7.38404 0.669 0.509 0.118205607
31 1.69 3.3125 1.67551 1.977 0.057 0.349489292
Table 3
Table showing data for various mood/quality-of-life variables — the tasks administered and the number of subjects for the particular task (n) are shown. Mean and standard error (SE)
before lacosamide administration (‘Pre’), after lacosamide (‘Post’) and difference (‘Diff’) are shown, as well as ‘t’ and ‘p’ values.
Task n Mean Pre SE Pre Mean Post SE Post Mean Diff SE Diff t p Effect size — Cohen's d
Beck Depression Inventory — Second Edition 34 13.74 2.018 9.26 1.527 −4.4706 1.69472 −2.638 0.013 −0.452406046
Quality of Life—89 attention concentration T score 32 44.44 2.186 46.63 1.982 2.1875 1.90576 1.148 0.26 0.202910661
QOLIE 89 memory 32 46.44 2.051 56.5 9.017 10.0625 9.39596 1.071 0.292 0.189317057
QOLIE 89 language 32 43 2.318 42.66 2.217 −0.3438 1.87331 −0.183 0.856 −0.032443017
QOLIE 89 overall score 32 43.91 2.07 46.41 2.27 2.5 1.6332 1.531 0.136 0.270598664
Proﬁle of Mood States (POMS) tension 34 11.38 1.169 10.24 1.402 −1.1471 1.05223 −1.09 0.284 −0.186961051
POMS depression 34 14.44 2.423 11.38 2.12 −3.0588 1.73767 −1.76 0.088 −0.301886936
POMS anger 34 9.56 1.565 8.97 1.657 −0.5882 1.72489 −0.341 0.735 −0.058482261
POMS vigor 34 13.53 1.249 16.15 1.217 2.6176 1.17688 2.224 0.033 0.381444749
POMS fatigue 34 8.82 1.012 8.21 1.222 −0.6176 1.09367 −0.565 0.576 −0.096845965
POMS confusion 34 10.21 1.038 9.91 1.065 −0.2941 0.77567 −0.379 0.707 −0.065024732
POMS total mood disturbance 34 43.38 6.379 38.26 6.114 −5.1176 5.76976 −0.887 0.382 −0.15211398
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Self-reported AEs included mild headaches in 10 patients, dizziness
in 7, mild tiredness in 7, gastrointestinal symptoms (constipation/
diarrhea) in 7, memory/attention concerns in 4, irritability in 3, depres-
sive symptoms in 3, slurred speech in 1, and thirst in 1. The adverse
event proﬁle showed a baseline average score of 23.82 ± 1.77 at base-
line vs. 20.82 ± 1.90 after lacosamide (n = 34, t = 1.88, p = 0.06).
The neurotoxicity scale revealed a mean baseline score of 10.79 ±
1.21 vs. 10.68 ± 1.16 after lacosamide (n = 34, t = 0.9, p = 0.92).
3.3. Efﬁcacy/effectiveness
Mean seizure frequency decreased signiﬁcantly from 2.0 ± 2.55 sei-
zures per week at baseline to 1.02 ± 1.72 seizures per week at post-
treatment (t = 4.59, p b 0.0001) with a 50% responder rate seen in 18
patients (52.9%), seizure freedom in 3 (8.8%), and increase in frequency
in 4 (11.8%). There was no signiﬁcant difference for the Liverpool Sei-
zure Severity Scale, with a pretreatment mean score of 47.82 ± 3.79
vs. 46.57 ± 3.65 posttreatment (n = 34, t = 0.74, p = 0.46).
3.4. Cognitive outcomes
The Kolmogorov–Smirnov test showed the cognitive composite
to be normally distributed (Z = 0.401, p = 0.997). The two-sided
one-sample t-test was not statistically signiﬁcant (t = −0.343, p =
0.734), indicating no change in overall cognitive scores over the dura-
tion of the drug trial, assuming no adjustment for the effects of the
covariate predictors. In the full linear model, the residual was normally
distributed (Kolmogorov–Smirnov Z = 0.546, p = 0.927). The optimal
model from the regression (F = 9.43, p = 0.005) retained the inter-
cept and seizure frequency at the end of the drug trial (t = −3.07,
p = 0.005). This regression indicates that there was no signiﬁcant
change in overall cognitive scores over the duration of the drug trial
after adjusting for the linear effects of the covariates except for ﬁnal
seizure frequency, whichwas signiﬁcantly related to the cognitive com-
posite score. Individual test score comparisons can be seen in Table 2.
No single score reached statistical signiﬁcance. When individual pa-
tientswere considered, only 3 had signiﬁcant changeswith two patients
exhibiting signiﬁcant improvement and one exhibiting a signiﬁcant
worsening in the composite (Table 4).
3.5. Mood/quality-of-life outcomes
The Kolmogorov–Smirnov test showed the mood/quality-of-life
composite to be normally distributed (Z = 0.716, p = 0.685). The
two-sided one-sample t-test was not signiﬁcant (t = 0.191, p = 0.85),
indicating no change in mood/quality of life over the duration of the
drug trial, assuming no adjustment for the effects of the covariatepredictors. In the full linear model, the residual was normally distribut-
ed (Z = 0.775, p = 0.585). The optimal model from the regression
retained only the intercept. No covariates were statistically signiﬁcant.
There was thus no change in overall mood/quality of life over the dura-
tion of the study after adjusting for the linear effects of the covariates.
Individual test score comparisons can be seen in Table 3. No single
score reached statistical signiﬁcance. When individual patients were
considered, only 1 exhibited a signiﬁcant change which was an im-
provement in the composite (Table 4).
4. Discussion
To our knowledge, this study is the ﬁrst prospective examination of
the effects of lacosamide on cognition and mood with a comprehensive
neuropsychological battery in an adjunctive trial with patients with ep-
ilepsy. Findings from the present study support the assertion that
lacosamide has low risks of adverse mood effects. There also appear to
be low risks of an overall effect on cognition, although amultiple regres-
sion analysis showed an effect of seizure frequency on cognition. There
was also a signiﬁcant reduction in seizure frequency after the 24-week
trial of lacosamide which is supportive of prior studies that have
shown that lacosamide is effective as an adjunct therapy in refractory
partial epilepsy.
Our study examined cognition with a comprehensive prospec-
tive analysis of attention, concentration, psychomotor speed, verbal
and nonverbal learning, and ﬂuency and found that the addition of
lacosamide to the patient's baseline regimen did not result in signiﬁcant
changes in overall cognitive functions. Our results are consistent with
previous studies. IJff et al. [7] examined 33 patients with refractory
partial epilepsy in which lacosamide was added to their previous AED
regimen. Two psychometric tools were used: the SIDAED and the Com-
puterized Visual Searching Task (CVST). The SIDAED is a scale that as-
sesses 46 subjective complaints including general CNS irritability,
depressive symptoms, cognitive function, motor problems, visual com-
plaints, headache, cosmetic and dermatologic complaints, gastrointesti-
nal complaints, and sexuality and menses. The CVST assesses reaction
time on changing screens. The authors found that the CVST showed sig-
niﬁcantly faster information-processing reaction times at the second
evaluation. Surprisingly, the self-reported SIDAED showed an increase
in complaints about cognitive function after the addition of lacosamide.
The authors offered the phenomenon of “doing better, feelingworse” as
a potential explanation. However, because the cognitive assessment in
this study was limited to reaction times while the SIDAED assesses for
several other cognitive functions including memory, speech, and con-
centration, it is not possible to knowwhether these subjective/objective
divergences are due to limited objectivemeasures. In contrast with IJff's
ﬁndings, our patients did not report adverse effects or self-reported
cognitive problems. Our study differs from IJff's study in that we
used a comprehensive set of neuropsychological tests that are sensitive
measures of attention, concentration, verbal and nonverbal learning,
Table 4
Demographic details of subjects— age, sex, seizures perweek (baseline and after lacosamide treatment), antiepileptic drugs at the time of screening, dose of lacosamide at visit 4, and type
of epilepsy are shown. Negative direction for mood composite represents improvement in mood. Negative direction for cognitive composite represents worsening of cognitive function.
ID Age Sex Baseline
seizures/week
Posttreatment
seizures/week
Current AEDs Dose v4 Type of epilepsy Composite score
mood change
Composite score
cognitive change
1 21 1 0.5 0 LEV, PB 200 Symptomatic 0.178697575 −0.078598858
2 41 2 0.75 0 LAM, CNZ 200 Cryptogenic 0.976487291 0.153506423
3 37 2 0.75 0.727 LEV, OXC 100 Symptomatic 0.226460354 0.041991867
4 49 1 1.25 0.455 LAM, TOP 300 Cryptogenic −0.799912285 −0.296341901
5 36 2 4 1.591 LEV 300 Symptomatic −0.640890999 0.127705427
6 63 1 0.5 0.136 LEV, LAM 200 Cryptogenic 0.550621973 −0.535960511
7 43 2 0.5 0.5 PHT 250 Cryptogenic −0.290809067 0.058466186
8 55 2 0.5 0.091 LEV, CAR 200 Cryptogenic 0.564902514 0.250600029
9 32 1 6.25 4.045 LEV, OXC 200 Symptomatic 0.816851576 0.13595501
10 52 1 1.5 1.091 LEV, PB, CBZ 200 Cryptogenic 0.000891524 0.075274154
11 23 2 2 0.136 LVT 200 Cryptogenic −0.003612197 0.928971627a
12 19 2 0.5 0.909 LEV, GAB, OXC 300 Symptomatic −0.930569127 0.03094075
13 47 2 0.5 0.636 LAM, OXC 300 Cryptogenic 0.287455955 −0.447469947
14 33 2 0.75 0.091 LAM, ZON, CNZ, AZA 200 Cryptogenic −2.526750045a 0.252773266
15 23 2 3 0.591 CBZ, TOP 200 Symptomatic −0.061737751 −0.059623522
16 18 1 0.5 0.227 VPA, LEV 200 Cryptogenic 0.054526515 0.03732478
17 58 2 0.75 0.682 LEV, OXC 300 Cryptogenic −0.811121219 0.089224975
18 45 2 5 0.955 LEV 200 Cryptogenic 0.921853809 −0.657183894
19 48 2 0.75 0.909 LEV, CNZ 250 Cryptogenic −0.250755042 0.327168814
20 18 1 1.25 0.318 OXC 200 Symptomatic 0.418498537 −0.222867469
21 35 1 14 9 PHT, CNZ, TOP 400 Cryptogenic −0.014461594 −0.259786859
22 42 2 2.25 0.818 VPA, OXC 300 Cryptogenic 0.404117871 0.007488963
23 44 1 3.5 4.5 CBZ 200 Symptomatic 0.31190377 −1.188859438a
24 62 1 1 0.364 LEV, LAM, CBZ, ZON 200 Cryptogenic −0.080789404 −0.239652516
25 62 2 2.75 0.045 LEV 200 Cryptogenic −0.656464684 0.559815821
26 48 2 2 0.636 LEV, LAM, PHT 200 Cryptogenic −0.247991941 −0.160069615
27 42 1 0.5 0 OXC, CNZ 200 Cryptogenic −0.307038522 −0.217348184
28 38 2 1 0.545 ZON, OXC, GAB 300 Cryptogenic 0.317477374 −0.328854161
29 55 1 1 0.5 CBZ 400 Cryptogenic 0.110296667 0.139773858
30 19 1 1.5 1.182 LEV, CBZ 300 Symptomatic 0.043341876 0.796278405a
31 27 2 0.5 0.136 LEV, CBZ, VPA 200 Cryptogenic −0.396189014 0.513826532
32 21 2 3.5 1.455 LEV 200 Cryptogenic 0.712669165 −0.474817138
33 31 2 2 1.318 LEV, OXC, PB 200 Cryptogenic 0.895325578 0.297260351
34 24 2 1 0.045 VPA, ZON 200 Cryptogenic 0.009414343 −0.169996565
LEV= levetiracetam; PB=phenobarbital; LAM= lamotrigine; TOP= topiramate; CBZ= carbamezapine; PHT=phyenytoin; OXC=oxcarbazepine; ZON=zonisamide; VPA=valproic
acid; CNZ=clonazepam, GAB=gabapentin.
a ≥2 SD from the sample mean.
32 M.E. Lancman et al. / Epilepsy & Behavior 61 (2016) 27–33verbal ﬂuency, and psychomotor speed. The other principal difference
between the two studies is that we had a ﬁxed protocol while IJff's
study was done in a “naturalistic setting”. As a result, times for testing
varied from patient to patient. Helmstaedter and Witt [8] compared
cognitive functions in those receiving lacosamide (n = 44) with
topiramate (n = 15) and lamotrigine (n = 11) in a retrospective study
in a naturalistic outpatient setting. Patients were studied at baseline
and after a median follow-up interval of 32 weeks with the Epitrack
for executive function (response-inhibition, visuomotor speed, mental
ﬂexibility, visual motor planning, verbal ﬂuency, and workingmemory),
a German adaptation of the Rey Auditory Verbal Learning Test, a sub-
jective rating of self-perceived side effects (cognition, behavior, and
physical/physiological symptoms), and the QOLIE-10 for quality of life.
The authors concluded that objective and subjective measures demon-
strated that the cognitive side effect proﬁle of lacosamide is comparable
with that of lamotrigine and superior to topiramate. The main limita-
tions of this study were the small number of subjects in each subgroup
and its retrospective nature.
With regard to depression,mood, and quality of life, our ﬁndings are
consistent with previous reports; lacosamide does not appear to have
negative side effects onmood/quality of life. Moseley et al. [9] examined
the potential effects of lacosamide on depression and anxiety in a retro-
spective study of 91 patients with partial-onset epilepsy using the
Neurological Disorders Depression Inventory for Epilepsy (NDDI-E)
and the Generalized Anxiety Disorder—7-item scale (GAD-7). It was
concluded that lacosamide did not have a negative effect on depression
or anxiety. This study's main limitations are that it was a retrospective
chart review, not controlled and limited to the study of depressionand anxiety without assessing for other cognitive or behavioral do-
mains. Giorgi et al. [10] conducted a small prospective open study on
10 patients with partial epilepsy, comparing depression scores utilizing
the BDI and anxiety scoreswith the State Trait Anxiety Inventory (STAI)
before and after the administration of lacosamide. They found no sig-
niﬁcant changes. The primary limitation of this study was that it had
a very small sample and was limited to the assessment of depression
and anxiety only. While no signiﬁcant changes were determined on
the composite score that combined depression (BDI-II), mood (POMS),
and quality of life (QOLIE-89), individual depression scores, the BDI
and POMS depression, and vigor scores showed a trend towards
improvement after treatment with lacosamide. Along similar lines,
Moseley et al. [9] reported that lacosamide demonstrated a positive
effect on a speciﬁc subgroup of patients who initially presented with
elevated NDDI-E scores suggestive of major depressive disorder.
Lacosamide's mechanism of action enhances slow inactivation of
sodium channels [28], and as such, it might share the ‘mood stabilizing’
effect with other AEDs, including carbamazepine, oxcarbazepine,
valproate, and lamotrigine, all which enhance the fast inactivation of
sodium channels. Whether lacosamide has an antidepressant effect
will need to be further investigated.
In the current study, lacosamide was well-tolerated and efﬁcacious
with a signiﬁcant decrease in seizure frequency and 50% responder
rates which are comparable with those in larger studies [1–6]. The
most commonly reported AEs were mild headaches, dizziness, mild
tiredness, and gastrointestinal symptoms. These ﬁndings coincide
with most of the reported series [1–6]. Adverse events were mostly
mild and intermittent and were either not treated or treated
33M.E. Lancman et al. / Epilepsy & Behavior 61 (2016) 27–33symptomatically. No patient discontinued the study because of side ef-
fects. Furthermore, the adverse event proﬁle scores showed no signiﬁ-
cant differences and, in fact, showed a trend towards fewer side
effects after the addition of lacosamide. Similarly, the neurotoxicity
scale showed no statistically signiﬁcant difference.
This study is not without limitations including a small number of
patients and not being a randomized, blinded, and placebo-controlled
study. Additionally, although we has made every effort to reduce prac-
tice effects by using alternate versions of tests (in total, 4 of the 8 tests
that included both verbal and visual memory), there are 4/8 tests that
did not have an alternate version. Although we performed the retesting
6 months after the ﬁrst test and sought reference from the Practitioner's
guide to evaluating change with neuropsychological assessment instru-
ments [23] assessing the impact of retesting of these speciﬁc measures,
the inclusion of these 4 tests could be considered a limitation to the
study's conclusions. In addition, it is a possibility that the reduction in
seizures could have improved cognition and obscured possible effects
of lacosamide.
An interesting future research direction might be to examinemeans
and standard deviations of neurocognitive measures collected in the
current study to the same tests used in previous studies of other AEDs
as well as healthy controls. Moreover, randomized controlled studies
might provide additional necessary evidence of the effects of
lacosamide on cognition and mood.
In conclusion, this study's results suggest that lacosamide has low
risks of adverse cognitive andmood effects and is effective as an adjunct
therapy in refractory partial epilepsy.
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